Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a price target ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has been given an average rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the stock, Marketbeat.com ...

Bank of America Securities analyst Jason Zemansky maintained a Sell rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced that it will present at the 43rd Annual J.P. Morgan Healthcare ...

Madrigal Pharma has become the first drugmaker to claim FDA approval for a drug to treat metabolic dysfunction-associated steatohepatitis (MASH), an elusive target that has seen many other ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) rose 2% in after hours trading amid some takeover speculation. There's speculation that Madrigal (MDGL) may have attracted interest from a large ...

Madrigal said that all patients enrolled in MAESTRO-NASH - which include up to 2,000 in total - are continuing on therapy after the initial 52-week treatment period.

Infinity Pharmaceuticals Inc. 0.00% $90.76 ...

Austin-area robotic architecture firm ICON and pharmaceutical company Cassava Sciences combined to layoff over 120 workers ...

Liver Cirrhosis Therapies and Key Companies .Resmetirom: Madrigal Pharmaceuticals Inc. .Key Liver Cirrhosis Companies: Madrigal Pharmaceuticals Inc., Galectin Therapeutics, Akero Therapeutics ...